2seventy bio (NASDAQ:TSVT) Given Sell (D-) Rating at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of 2seventy bio (NASDAQ:TSVT) in a report released on Tuesday morning,Weiss Ratings reports.

A number of other equities analysts also recently commented on TSVT. Leerink Partnrs downgraded 2seventy bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 11th. Morgan Stanley lowered their target price on shares of 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating for the company in a research note on Friday, March 14th. Finally, Leerink Partners restated a “market perform” rating and issued a $5.00 price target (down from $9.00) on shares of 2seventy bio in a research note on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, 2seventy bio presently has a consensus rating of “Hold” and an average price target of $5.60.

2seventy bio Stock Up 0.4 %

Shares of TSVT stock opened at $4.96 on Tuesday. The firm has a 50 day moving average of $3.76 and a two-hundred day moving average of $3.74. The stock has a market capitalization of $259.60 million, a PE ratio of -2.67 and a beta of 1.04. 2seventy bio has a 52 week low of $2.29 and a 52 week high of $5.52.

2seventy bio (NASDAQ:TSVT) last released its earnings results on Tuesday, March 25th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.08). 2seventy bio had a negative net margin of 207.25% and a negative return on equity of 53.65%. The company had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $12.84 million. Analysts expect that 2seventy bio will post -1.46 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO William D. Baird III sold 5,092 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $4.95, for a total value of $25,205.40. Following the completion of the sale, the chief executive officer now directly owns 1,121,034 shares of the company’s stock, valued at approximately $5,549,118.30. This represents a 0.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of 2seventy bio stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $4.93, for a total transaction of $25,350,607.23. The disclosure for this sale can be found here. Insiders have sold 5,152,093 shares of company stock worth $25,400,018 in the last ninety days. 7.20% of the stock is owned by corporate insiders.

Institutional Trading of 2seventy bio

A number of large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of 2seventy bio in the fourth quarter valued at about $32,000. BNP Paribas Financial Markets acquired a new position in 2seventy bio in the 4th quarter valued at about $35,000. ProShare Advisors LLC acquired a new position in 2seventy bio in the 4th quarter valued at about $48,000. Raymond James Financial Inc. purchased a new stake in 2seventy bio during the 4th quarter valued at approximately $52,000. Finally, Intech Investment Management LLC lifted its position in 2seventy bio by 41.1% during the 4th quarter. Intech Investment Management LLC now owns 20,688 shares of the company’s stock worth $61,000 after acquiring an additional 6,030 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.